Enanta Pharmaceuticals CEO Jay Luly's 2019 pay slips 1% to $4.5M

Enanta Pharmaceuticals reports 2019 executive compensation

By ExecPay News

Published: January 17, 2020

Enanta Pharmaceuticals reported fiscal year 2019 executive compensation information on January 17, 2020.
In 2019, five executives at Enanta Pharmaceuticals received on average a compensation package of $2.2M, a 4% increase compared to previous year.
Average pay of disclosed executives at Enanta Pharmaceuticals
Jay R. Luly, Chief Executive Officer, received $4.5M in total, which decreased by 1% compared to 2018. 68% of Luly's compensation, or $3M, was in option awards. Luly also received $337K in non-equity incentive plan, $642K in salary, $458K in stock awards, as well as $19K in other compensation.
For fiscal year 2019, the median employee pay was $260,099 at Enanta Pharmaceuticals. Therefore, the ratio of Jay R. Luly's pay to the median employee pay was 17 to one.
Yat Sun Or, Chief Scientific Officer, received a compensation package of $1.6M, which increased by 7% compared to previous year. 55% of the compensation package, or $890K, was in option awards.
Nathalie Adda, Chief Medical Officer, earned $1.6M in 2019, a 7% increase compared to previous year.
Paul J. Mellett, Chief Financial Officer, received $1.5M in 2019, which increases by 8% compared to 2018.
Nathaniel S. Gardiner, General Counsel, earned $1.5M in 2019, a 9% increase compared to previous year.
Enanta Pharmaceuticals' fiscal year ends on September 30.

Related executives

Jay Luly

Enanta Pharmaceuticals

Chief Executive Officer

Yat Or

Enanta Pharmaceuticals

Chief Scientific Officer

Nathalie Adda

Enanta Pharmaceuticals

Chief Medical Officer

Paul Mellett

Enanta Pharmaceuticals

Chief Financial Officer

Nathaniel Gardiner

Enanta Pharmaceuticals

General Counsel

You may also like

Source: SEC filing on January 17, 2020.